EVALUATING THE COST-EFFECTIVENESS OF ONCE-WEEKLY SEMAGLUTIDE 1 MG VERSUS EMPAGLIFLOZIN 25 MG FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES IN THE UK SETTING

被引：0
|
作者：
Capehorn, M. [1 ]
Hallen, N. [2 ]
Hunt, B. [3 ]
机构：
[1] Rotherham Inst Obes, Rotherham, S Yorkshire, England
[2] Novo Nordisk AS, Soborg, Denmark
[3] Ossian Hlth Econ & Commun, Basel, Switzerland
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB42
引用
收藏
页码：S512 / S512
页数：1
相关论文
共 50 条
  • [21] The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK
    Viljoen, Adie
    Chubb, Barrie
    Malkin, Samuel J. P.
    Berry, Sasha
    Hunt, Barnaby
    Bain, Stephen C.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2023, 24 (06): : 895 - 907
  • [22] Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK
    Viljoen, Adie
    Hoxer, Christina S.
    Johansen, Pierre
    Malkin, Samuel
    Hunt, Barnaby
    Bain, Stephen C.
    DIABETES OBESITY & METABOLISM, 2019, 21 (03): : 611 - 621
  • [23] Cost-Effectiveness of Once-Weekly Semaglutide 1.0 mg vs. Dulaglutide 1.5 mg as Add-On to Metformin in the Treatment of Type 2 Diabetes in Canada
    Johansen, Pierre
    Hakan-Bloch, Jonas
    Liu, Aiden R.
    Persson, Sofie
    Grip, Emilie Toresson
    DIABETES, 2018, 67
  • [24] Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting (Mar, 10.1007/s40258-022-00726-z, 2022)
    Stafford, Sara
    Bech, Peter G.
    Fridhammar, Adam
    Miresashvili, Nino
    Nilsson, Andreas
    Willis, Michael
    Liu, Aiden
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2022, 20 (04) : 623 - 623
  • [25] COST-EFFECTIVENESS ANALYSIS OF ONCE-WEEKLY SEMAGLUTIDE VERSUS POLYETHYLENE GLYCOL LOXENATIDE FOR TREATMENT OF TYPE 2 DIABETES IN CHINA
    Liu, L.
    Zhen, R.
    Ung, C. O. L.
    Shen, Y.
    Zhang, Y.
    Han, S.
    Jia, R.
    Qiao, J.
    Hu, H.
    Guo, L.
    VALUE IN HEALTH, 2022, 25 (12) : S116 - S116
  • [26] The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China
    Shuyan Gu
    Jinghong Gu
    Xiaoyong Wang
    Xiaoling Wang
    Lu Li
    Hai Gu
    Biao Xu
    Health Economics Review, 14
  • [27] The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China
    Gu, Shuyan
    Gu, Jinghong
    Wang, Xiaoyong
    Wang, Xiaoling
    Li, Lu
    Gu, Hai
    Xu, Biao
    HEALTH ECONOMICS REVIEW, 2024, 14 (01)
  • [28] The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
    Vidal, Josep
    Malkin, Samuel J. P.
    Hunt, Barnaby
    Martin, Virginia
    Hallen, Nino
    Javier Ortega, Francisco
    DIABETES THERAPY, 2020, 11 (02) : 509 - 521
  • [29] The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
    Josep Vidal
    Samuel J. P. Malkin
    Barnaby Hunt
    Virginia Martín
    Nino Hallén
    Francisco Javier Ortega
    Diabetes Therapy, 2020, 11 : 509 - 521
  • [30] Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden
    Ericsson, Asa
    Fridhammar, Adam
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (10) : 997 - 1005
12345